Fighting cardiovascular disease with acne drug

Researchers from the European Molecular Biology Laboratory in Heidelberg and Stanford University have found the cause of dilated cardiomyopathy – a leading cause of heart failure – and identified a potential treatment for it: a drug already used to treat acne. The study was published on 8 September in Cell Reports. The original press release can be found here: https://www.embl.org/news/science/cardiovascular-disease/

Dilated cardiomyopathy (DCM) is a leading cause of heart failure, affecting 1 in 250 people. The disease is characterised by an increase in size of the left ventricle of the heart. The stretched heart muscle is then unable to pump blood as effectively, which can lead to irregular heartbeat, heart valve problems, and ultimately heart failure. As the leading cause of heart failure, DCM is the most common reason for carrying out a heart transplant, which is only offered in end-stage heart failure when all other treatment options and lifestyle changes have failed. Despite years of work to improve patient survival after transplantation, the 10-year survival rate is still only 50%.

“Currently DCM is treated with medicines used for heart failure in general, their function being to lower strain on the heart. Patient health would be significantly improved with targeted treatment options prior to the need for a heart transplant,” explains Lars Steinmetz, from the European Molecular Biology Laboratory in Heidelberg and Stanford University. “We need therapeutic strategies that target the cause of the disease in a personalised medicine approach.” The new study by the Steinmetz group, in cooperation with Mark Mercola’s lab at Stanford University, provides fresh insight into this deadly disease, hinting at potential new treatment possibilities.


The researchers had the unique opportunity to study a single family with inherited DCM to understand the cause of their disease. Because it’s an inherited disease, studying the genome, or complete set of DNA and genes, can provide important information on the mutation causing the disease. By studying a family, the researchers were able to look for differences in the regions of the genome that carry instructions for making proteins, in family members who had died with a diagnosis of DCM, had been diagnosed with DCM, or were unaffected by DCM. This comparison allowed them to find a single mutation (P633L) in a gene coding for a protein called RBM20, which was disease causing. Although the mutation was previously unknown, changes in RBM20 are known to cause a severe form of inherited DCM that is often associated with early onset of end-stage heart failure.

“When we started the project, we wanted to identify the mutation causing the disease in this family,” explains Steinmetz, who is also the founder of the Steinmetz Cardiomyopathy Fund, by which most of the study was financed. Francesca Briganti, from the Mercola Lab, adds: “When we found the new mutation, we had to demonstrate that this is indeed the pathogenic mutation – there were already over 30 genes linked to the disease beforehand. We did this by showing that the mutation causes splicing and cellular contraction defects using in vitro cell models.”

The researchers used a combination of patient-derived cells and genome-edited cells. This process of genome editing involved making specific changes to the DNA of the cells, to introduce the RBM20 mutation (P633L) into patient-derived cells known as induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). This gave the researchers the chance to understand how the mutation was causing DCM and also to propose a potential treatment option. “We were lucky. We searched the database and found a fitting compound. Going from finding the disease gene to finding the potential solution overnight was easy with the open databases at EMBL’s European Bioinformatics Institute,” says Steinmetz.

The team identified a chemical called all-trans retinoic acid (ATRA) as a potential treatment of DCM. ATRA regulates RBM20, and can partially fix the defects in the altered cells. ATRA is a drug used for the treatment of acne and a type of leukaemia called acute promyelocytic leukaemia. In this case, Steinmetz reasoned that increasing expression of RBM20 might overcome the insufficient expression of this protein that is seen in patients who have one functioning and one mutated copy of the gene.

“This is a promising result in approaching RBM20-deficient DCM,” explains Steinmetz. “In addition, the general approach and the strategy we used in this study could work for a number of other dominant diseases!”

Links

Source Article
Lars Steinmetz et al. iPSC modelling of RBM20-deficient DCM identifies upregulation of RBM20 as a therapeutic strategy. Cell, published 8 September 2020
DOI: 10.1016/j.celrep.2020.108117

Über EMBL Heidelberg

EMBL is Europe’s flagship laboratory for the life sciences. We are an intergovernmental organisation established in 1974 and are supported by 27 member states, 2 prospective member states and 2 associate member states.

EMBL performs fundamental research in molecular biology, studying the story of life. We offer services to the scientific community; train the next generation of scientists and strive to integrate the life sciences across Europe.

We are international, innovative and interdisciplinary. We are more than 1800 people, from over 80 countries, operating across six sites in Barcelona (Spain), Grenoble (France), Hamburg (Germany), Heidelberg (Germany), Hinxton (UK) and Rome (Italy). Our scientists work in independent groups and conduct research and offer services in all areas of molecular biology.

Our research drives the development of new technology and methods in the life sciences. We work to transfer this knowledge for the benefit of society.www.embl.org

Firmenkontakt und Herausgeber der Meldung:

EMBL Heidelberg
Meyerhofstraße 1
69117 Heidelberg
Telefon: +49 (6221) 387-0
Telefax: +49 (6221) 387-8306
http://www.embl.de

Ansprechpartner:
Mathias Jäger
Press Officer
Telefon: +49 (6221) 387-8726
Fax: +49 (176) 62397500
E-Mail: mathias.jaeger@embl.org
Für die oben stehende Pressemitteilung ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.

counterpixel